Literature DB >> 15899216

Integrating trastuzumab in the treatment of breast cancer. Current status and future trends.

Alberto Ocaña, César A Rodríguez, Juan J Cruz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15899216     DOI： 10.1007/bf02708741

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN： 1699-048X            Impact factor:   3.405


× No keyword cloud information.
  23 in total

1.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.

Authors:  M F Press; L Bernstein; P A Thomas; L F Meisner; J Y Zhou; Y Ma; G Hung; R A Robinson; C Harris; A El-Naggar; D J Slamon; R N Phillips; J S Ross; S R Wolman; K J Flom
Journal:  J Clin Oncol       Date:  1997-08       Impact factor: 44.544

2.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

3.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

4.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Authors:  R M Hudziak; G D Lewis; M Winget; B M Fendly; H M Shepard; A Ullrich
Journal:  Mol Cell Biol       Date:  1989-03       Impact factor: 4.272

Review 5.  Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).

Authors:  M X Sliwkowski; J A Lofgren; G D Lewis; T E Hotaling; B M Fendly; J A Fox
Journal:  Semin Oncol       Date:  1999-08       Impact factor: 4.929

Review 6.  Mechanism of action of trastuzumab and scientific update.

Authors:  J Baselga; J Albanell; M A Molina; J Arribas
Journal:  Semin Oncol       Date:  2001-10       Impact factor: 4.929

7.  Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

Authors:  F Michael Yakes; Wichai Chinratanalab; Christoph A Ritter; Walter King; Steven Seelig; Carlos L Arteaga
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

8.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

9.  Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories.

Authors:  Karen A Gelmon; John Mackey; Shailendra Verma; Stan Z Gertler; Nicholas Bangemann; Paul Klimo; Andreas Schneeweiss; Karl Bremer; Denis Soulieres; Katia Tonkin; Richard Bell; Bernhard Heinrich; Debjani Grenier; Reg Dias
Journal:  Clin Breast Cancer       Date:  2004-04       Impact factor: 3.225

10.  Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.

Authors:  Mark D Pegram; Gottfried E Konecny; Carminda O'Callaghan; Malgorzata Beryt; Richard Pietras; Dennis J Slamon
Journal:  J Natl Cancer Inst       Date:  2004-05-19       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.